Zacks Research Weighs in on Novartis’ Q2 Earnings (NYSE:NVS)

Novartis AG (NYSE:NVS) – Analysts at Zacks Research raised their Q2 2025 earnings estimates for Novartis in a research report issued on Tuesday, May 13th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $2.17 for the quarter, up from their previous estimate of $2.14. The consensus estimate for Novartis’ current full-year earnings is $8.45 per share. Zacks Research also issued estimates for Novartis’ Q3 2025 earnings at $2.24 EPS, Q4 2025 earnings at $2.07 EPS, FY2025 earnings at $8.76 EPS, Q1 2026 earnings at $2.24 EPS, Q2 2026 earnings at $2.27 EPS, Q3 2026 earnings at $2.23 EPS, FY2026 earnings at $8.93 EPS, Q1 2027 earnings at $2.36 EPS and FY2027 earnings at $9.48 EPS.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.16. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The company had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $12.92 billion. During the same period in the previous year, the firm earned $1.80 earnings per share. Novartis’s quarterly revenue was up 11.9% compared to the same quarter last year.

Other equities analysts also recently issued reports about the stock. Morgan Stanley began coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an “underweight” rating on the stock. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Thursday, February 13th. Barclays reaffirmed an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Finally, BNP Paribas upgraded shares of Novartis to a “strong-buy” rating in a research report on Tuesday, April 15th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Price Performance

Shares of NVS stock opened at $108.37 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The firm’s 50-day moving average is $109.72 and its two-hundred day moving average is $105.76. Novartis has a 12 month low of $96.06 and a 12 month high of $120.92. The company has a market capitalization of $228.92 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 1.70 and a beta of 0.60.

Hedge Funds Weigh In On Novartis

Several institutional investors have recently bought and sold shares of the company. Human Investing LLC purchased a new stake in shares of Novartis during the 4th quarter worth approximately $25,000. Raiffeisen Bank International AG acquired a new stake in Novartis in the 4th quarter valued at about $25,000. Nexus Investment Management ULC purchased a new position in Novartis during the 1st quarter valued at about $25,000. WPG Advisers LLC acquired a new position in Novartis during the first quarter worth about $25,000. Finally, Tsfg LLC lifted its holdings in shares of Novartis by 366.0% in the first quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after purchasing an additional 183 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Dividend Announcement

The company also recently disclosed a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were paid a $3.8695 dividend. The ex-dividend date was Wednesday, March 12th. Novartis’s dividend payout ratio is currently 40.47%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.